Loading
Two small doses of radiotherapy did not control follicular and marginal zone lymphoma as well as the standard twelve, with more than three times the rate of regrowth in the treated area, so 24 Gy remains the standard and 4 Gy is for palliation.
UK phase 3 non-inferiority trial at 43 centres: 614 target sites in patients with follicular or marginal zone lymphoma were randomised to 24 Gy in 12 fractions (299 sites) or 4 Gy in 2 fractions (315 sites) between 2006 and 2011. The primary endpoint was time to local progression in the irradiated field.
After a median follow-up of 26 months there were 21 local progressions after 24 Gy and 70 after 4 Gy; time to local progression with 4 Gy was not non-inferior (hazard ratio 3.42).
24 Gy in 12 fractions is the standard radiotherapy dose for indolent lymphoma when durable local control is the aim; 4 Gy remains useful for palliation.
Shares FoRT, FORTplus, Marginal zone lymphoma, The Lancet Oncology.
Shares Lymphoma treatments that did not work: the negative trials worth knowing, FORTplus, Marginal zone lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting.
Shares Marginal zone lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma.
Shares Marginal zone lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma.
Shares FORTplus, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma.
Shares FORTplus, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma.
Shares Marginal zone lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma.